News

A combination of immune checkpoint blockade and targeted therapies that block normal DNA damage repair achieved significant tumor regression in mouse models of small cell lung cancer, suggesting a promising new approach for treating patients with this aggressive cancer.

BRAF-targeted therapies render resistant melanoma more sensitive to the attack of killer T cells. The findings pave the way in developing therapy for patients that have become resistant to BRAF inhibitors.

A combination of two drugs – one of them an immunotherapy agent – could become a new standard, first-line treatment for patients with metastatic kidney cancer, says an investigator from Dana-Farber Cancer Institute, reporting results from a Phase 3 clinical trial.

Stem cell technologies show promise for treating Parkinson's disease and may play an increasing role in alleviating at least the motor symptoms, if not others, in the decades to come.

Animal venoms are the subject of study at research center based at the Butantan Institute in São Paulo. But in this case, the idea is not to find antidotes, but rather to use the properties of the venoms themselves to identify molecular targets of diseases and, armed with that knowledge, develop new compounds that can be used as medicines.

A research team at the University of Louisville has discovered that an immune checkpoint molecule they developed for cancer immunotherapy, also protects against future development of multiple types of cancer when administered by itself.

For the first time ever, researchers are comprehensively sequencing the human immune system, which is billions of times larger than the human genome.

UNIGE researchers demonstrate the ease of some human pancreatic cells to make insulin. In diabetes, this type of cell conversion could compensate for the loss or dysfunction of cells that naturally produce this hormone.

Using the measles virus vector; researchers have trimmed the multi-vector process with four reprogramming factors down to a single “one cycle” vector process.

Researchers at University of Utah Health detailed the function of cone snail insulins, bringing them one step closer to developing a faster-acting insulin to treat diabetes.